Partial Cellular Reprogramming Reaches Its First Human Trial

Every cell in your body keeps the same DNA from birth to death. What actually changes with age isn't the genetic code itself but the epigenome — the layer of chemical marks that determines which genes are switched on or off in a given cell. Over decades, those marks drift, and cells gradually lose some of the regulatory patterns that defined their younger state.

Shinya Yamanaka's Nobel Prize-winning discovery showed that four specific transcription factors — often called the Yamanaka factors — could reset a mature cell's epigenome all the way back to a pluripotent stem cell state. That's a powerful result, but full reprogramming is also risky: pushed too far, a cell can lose its identity entirely, which is one reason full reprogramming hasn't moved toward direct human application.

A therapy called ER-100 takes a narrower approach, often described as partial reprogramming. It delivers three of the four Yamanaka factors — OCT4, SOX2, and KLF4 — deliberately omitting the fourth, which is more strongly associated with unwanted cellular dedifferentiation. The goal is to nudge a cell's epigenetic state back toward a younger pattern without erasing its identity as, say, a retinal cell or a neuron.

In primate studies, this approach restored function in aged retinal cells and recovered vision that had been lost, building on earlier mouse research from a separate lab showing similar epigenetic reprogramming could reverse vision loss. On the strength of that animal data, the FDA cleared ER-100 in January 2026 to begin human testing, delivered by injection into the eye to treat optic nerve conditions.

This is a genuinely significant milestone: it's the first partial cellular reprogramming therapy to reach a human clinical trial. Everything demonstrated so far — including the retinal recovery — has been in animals and primates, and Phase 1 trials exist specifically to test safety in a small human population before any claim about efficacy can be made. That distinction matters; early clinical trial status is not the same as a validated treatment.

Why this matters for tracking: if partial reprogramming approaches progress through human trials, one of the first practical applications will likely be organ- or tissue-specific, rather than whole-body. Tracking function in the systems most relevant to you — vision, cognition, cardiovascular markers — over time gives you the kind of personal baseline that will matter if and when these therapies move beyond narrow clinical indications.